Authors
Christoph D Spinner, Robert L Gottlieb, Gerard J Criner, José Ramón Arribas López, Anna Maria Cattelan, Alex Soriano Viladomiu, Onyema Ogbuagu, Prashant Malhotra, Kathleen M Mullane, Antonella Castagna, Louis Yi Ann Chai, Meta Roestenberg, Owen Tak Yin Tsang, Enos Bernasconi, Paul Le Turnier, Shan-Chwen Chang, Devi SenGupta, Robert H Hyland, Anu O Osinusi, Huyen Cao, Christiana Blair, Hongyuan Wang, Anuj Gaggar, Diana M Brainard, Mark J McPhail, Sanjay Bhagani, Mi Young Ahn, Arun J Sanyal, Gregory Huhn, Francisco M Marty, GS-US-540-5774 Investigators
Publication date
2020/9/15
Journal
Jama
Volume
324
Issue
11
Pages
1048-1057
Publisher
American Medical Association
Description
Importance
Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
Objective
To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment.
Design, Setting, and Participants
Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen saturation >94%) enrolled from March 15 through April 18, 2020, at 105 hospitals in the United States, Europe, and Asia. The date of final follow-up was May 20, 2020.
Interventions
Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n …
Scholar articles
CD Spinner, RL Gottlieb, GJ Criner, JRA López… - Jama, 2020